---
title: 'Associate Director, HCP Promotional Marketing at Summit Therapeutics'
canonical: 'https://feeny.ai/job/associate-director-hcp-promotional-marketing-summit-therapeutics-princeton-nj-jx7vmryd049z'
type: 'job'
last_seen: '2026-09-04'
---

# Associate Director, HCP Promotional Marketing at Summit Therapeutics

- **Company:** Summit Therapeutics
- **Location:** Princeton NJ, United States
- **Compensation:** $174k–$205k
- **Posted:** 2026-08-13
- **Last confirmed live:** 2026-09-04
- **Apply:** https://job-boards.greenhouse.io/summittherapeutics/jobs/4368623009

## Job description

About Summit:

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence.

Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:

Non-small Cell Lung Cancer (NSCLC)

- HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI.

- HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC.

- HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.

Colorectal Cancer (CRC)

- HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy.

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.

Overview of Role:

The Associate Director of HCP Promotional Marketing will support the implementation and execution of brand strategy and core messaging for our NSCLC indications, helping to bring a clear, compelling brand narrative to life for HCPs. In this role, you will play a key part in translating strategy into effective field-facing and scientific engagement experiences.

Reporting to the Director of HCP Promotional Marketing, you will partner closely with cross-functional teams to ensure consistent pull through of messaging across channels and touchpoints. This role offers the opportunity to serve as a strong operational leader, contributing to high quality execution while building influence and expertise within a dynamic, launch focused organization.

Role and Responsibilities:

- Lead execution of the HCP brand strategy and core messaging for NSCLC indications, ensuring strong pull-through with the US field sales team and across key promotional touchpoints
- Serve as the marketing partner for the field, translating brand strategy and complex scientific concepts into clear, actionable execution guidance to drive effective HCP engagement
- Support the development, review, and approval of compliant derivative promotional materials that extend core brand messaging across channels
- Support planning and execution of promotional congress and major meeting activities
- Partner closely with Sales Leadership and Field Learning & Development to support field meetings, training material, and ongoing field enablement initiatives
- Monitor field feedback, marketplace insights, and competitive dynamics to inform ongoing optimization of messaging and execution
- Translate clinical data and strategic direction into compelling, compliant derivative promotional materials
- Support refinement of messaging based on evolving data, competitive landscape, and field insights
- Collaborate cross-functionally with Medical, Legal, Regulatory, Market Access, and Insights to ensure high-quality, compliant execution
- Travel as needed to support congresses and key business priorities
- All other duties as assigned.

Experience, Education and Specialized Knowledge and Skills:

- Bachelor's degree in Business, Marketing, or a related field; MBA or advanced degree preferred
- Minimum of 8+ years of pharmaceutical or biotech commercial experience, including HCP marketing experience in oncology
- Demonstrated experience supporting commercial launch activities and/or pre-launch activities
- Strong scientific acumen with demonstrated ability to interpret and translate complex oncology data into impactful, compliant HCP materials and field communications
- Proven project management skills with ability to manage multiple workstreams in a fast-paced, launch-focused environment
- Excellent communication skills with the ability to influence and lead through collaboration without direct authority
- Strong cross-functional experience with Marketing, Insights, Market Access, Medical, Legal, and Compliance
- Track record of operating with high integrity and maintaining compliance with regulatory, legal, and operational standards
- Ability to thrive in evolving, dynamic, and fast-paced pre-launch or launch-phase environments with shifting data and priorities
- Willingness to travel as business needs require

This is the pay for this position

Pay Transparency $174,000—$204,500 USD

Actual compensation packages are based on several factors that are unique to each candidate, including but not limited to skill set, depth of experience, certifications, and specific work location. This may be different in other locations due to differences in the cost of labor. The total compensation package for this position may also include bonus, stock, benefits and/or other applicable variable compensation.

Summit does not accept referrals from employment businesses and/or employment agencies in respect of the vacancies posted on this site. All employment businesses/agencies are required to contact Summit’s Talent Acquisition team at recruiting@smmttx.com to obtain prior written authorization before referring any candidates to Summit.

Summit Therapeutics Inc. is an Equal Opportunity Employer and takes pride in creating and maintaining diverse environment. We do not discriminate in recruitment, hiring, training or promotion or any other employment practices for reasons of race, color, religion, gender, national origin, age, sexual orientation, marital or veteran status, disability, or any other legally protected status.

## About Summit Therapeutics

## Company Overview
- **One-liner**: Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on discovering, developing, and commercializing novel bispecific antibody therapies, with its lead candidate ivonescimab targeting PD-1 and VEGF for multiple solid tumors.
- **Entity Type**: Public (NASDAQ: SMMT)
- **Headquarters**: Miami, Florida, USA (with additional offices in Palo Alto, CA; Princeton, NJ; Oxford, UK; and Dublin, Ireland)
- **Founded**: 2003
- **Founders**: Not publicly disclosed on the company website; the company was founded in 2003.

## Core Business
- **Primary industry**: Biopharmaceuticals / Oncology
- **Target customers**: B2B (healthcare providers, patients, and caregivers) with a focus on resolving serious unmet medical needs in oncology
- **Mission statement**: "To resolve serious, unmet medical needs for the betterment of overall human health." [smmttx.com](https://smmttx.com/company/about-us/default.aspx)

## Products & Services
- **Ivonescimab (SMT112)**: A novel, potential first-in-class investigational bispecific antibody targeting both PD-1 and VEGF. It is designed to combine immunotherapy (PD-1 blockade) with anti-angiogenesis (VEGF blockade) into a single molecule. Currently being studied in several global Phase 3 clinical trials for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and head and neck squamous cell carcinoma (HNSCC). Licensed from Akeso, Inc. (HKEX: 9926.HK) for territories including the U.S., Canada, Europe, Japan, Latin America, the Middle East, and Africa. [smmttx.com](https://smmttx.com/pipeline/default.aspx)

## Market Standing
- **Valuation/Market Cap**: Approximately $2.7 billion (as of recent data) [linkedin.com](https://www.linkedin.com/company/summit-therapeutics)
- **Key Metric**: Annual revenue of approximately $705,000 (reported). The company is pre-commercialization and heavily investing in R&D. Total funding raised since IPO (2015) is not disclosed, but the company has a strong cash position from equity offerings.
- **Notable Investors/Partners**: Akeso, Inc. (key licensing partner for ivonescimab). The company is publicly traded with institutional and retail investors.
- **Growth Signals**: 
  - Headcount grew 72.5% year-over-year to 244 employees. [linkedin.com](https://www.linkedin.com/company/summit-therapeutics)
  - Multiple global Phase 3 trials actively recruiting (HARMONi, HARMONi-3, HARMONi-7, HARMONi-GI3, ILLUMINE).
  - Over 4,000 patients have been treated with ivonescimab across all clinical trials globally. [smmttx.com](https://smmttx.com/pipeline/default.aspx)
  - Achieved Great Place to Work® Certification. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx)

## Competitive Advantages
- **Novel Mechanism**: Ivonescimab is a first-in-class bispecific antibody targeting both PD-1 and VEGF simultaneously, potentially offering superior efficacy and fewer side effects compared to combination therapies.
- **Speed and Execution**: The company emphasizes "high-speed execution in commercialization" and has rapidly initiated multiple Phase 3 trials.
- **Global Reach**: Licensed territories cover major markets (U.S., Canada, Europe, Japan, Latin America, Middle East, Africa) with a strong partner (Akeso) in the rest of the world.
- **Strong Balance Sheet**: With a $2.7B market cap and public listing, the company has access to capital markets to fund its pipeline.

## Strategic Focus
- **Current priorities**: Advancing ivonescimab through Phase 3 clinical trials across multiple solid tumor indications (NSCLC, CRC, HNSCC), with the goal of regulatory approval and commercialization.
- **Future direction**: Expanding the pipeline into additional solid tumors and leveraging the bispecific platform for future therapies. The company is focused on becoming a leading oncology player.
- **Near-term milestones**: Data readouts from ongoing Phase 3 trials, potential regulatory submissions, and building commercial infrastructure.

## Why Work Here
- **Culture**: The company has achieved Great Place to Work® Certification, indicating a positive, supportive, and fulfilling work environment. Core values include Commitment to People, Integrity, Passion for Excellence, Purposeful Urgency, Accountability, and Collaboration. [smmttx.com](https://smmttx.com/careers/careers-overview/default.aspx)
- **Work Environment**: Fast-paced, high-energy atmosphere focused on innovation and collaboration. The company emphasizes "making a significant difference in patients’ lives."
- **Benefits (U.S.)**: 
  - 401(k) with 6% employer match
  - Employee Stock Purchase Plan (ESPP) with 15% discount up to the annual federal limit
  - Flexible Spending Account
  - Commuter Benefit
  - Onsite lunch provided
- **Benefits (U.K.)**: 
  - Private Medical Insurance
  - Employee Assistance Program
  - Life Assurance Policy
  - Company Pension Contributions
  - ESPP
- **Remote/Hybrid Policy**: Not explicitly stated, but multiple office locations suggest a hybrid or on-site presence is expected for many roles.
- **Open Roles**: 25 active job postings (as of recent data) including Senior Director of Sales Operations, Clinical Scientists, Medical Science Liaisons, and Drug Product MSAT roles. [greenhouse.io](https://job-boards.greenhouse.io/summitherrapeutics)
- **Headcount Growth**: 72.5% year-over-year growth signals a scaling organization with opportunities for career advancement.

## Sources
1. [smmttx.com - About Us](https://smmttx.com/company/about-us/default.aspx)
2. [smmttx.com - Investor Relations Overview](https://www.smmttx.com/overview/default.aspx)
3. [smmttx.com - Pipeline](https://smmttx.com/pipeline/default.aspx)
4. [smmttx.com - Careers Overview](https://smmttx.com/careers/careers-overview/default.aspx)
5. [linkedin.com - Summit Therapeutics Company Page](https://www.linkedin.com/company/summit-therapeutics)
6. [greenhouse.io - Summit Therapeutics Careers](https://job-boards.greenhouse.io/summitherrapeutics)

## Other roles at Summit Therapeutics

- [Director, Commercial Analytics & Information](https://feeny.ai/job/director-commercial-analytics-information-summit-therapeutics-princeton-4sy7b3h9tjvz) — Princeton, NJ
- [Director, Marketing Operations](https://feeny.ai/job/director-marketing-operations-summit-therapeutics-princeton-5kjc188q3z1y) — Princeton, NJ
- [Project Manager - CONTRACT](https://feeny.ai/job/project-manager-contract-summit-therapeutics-princeton-nj-mjpba1rbgzgc) — Princeton NJ, United States
- [Senior Manager, CRM IT](https://feeny.ai/job/senior-manager-crm-it-summit-therapeutics-princeton-nj-9q5d6bn5sa0f) — Princeton NJ, United States
- [IT Business Analyst - G&A](https://feeny.ai/job/it-business-analyst-g-a-summit-therapeutics-palo-alto-8xxzscj7r2ez) — Palo Alto, CA
- [IT Helpdesk Analyst](https://feeny.ai/job/it-helpdesk-analyst-summit-therapeutics-palo-alto-xkn1kh9je3fc) — Palo Alto, CA
- [Associate Director, Project Management - Medical Affairs (Princeton, NJ or Palo Alto, CA)](https://feeny.ai/job/associate-director-project-management-medical-affairs-princeton-nj-or-palo-alto-h21rbxapf222) — Princeton NJ, United States
- [Senior Medical Science Liaison (South)](https://feeny.ai/job/senior-medical-science-liaison-south-summit-therapeutics-united-states-jmrft1h5njy5) — United States
- [Senior Medical Science Liaison (Texas)](https://feeny.ai/job/senior-medical-science-liaison-texas-summit-therapeutics-united-states-1nxejb2p96nq) — United States
- [Senior Medical Science Liaison (Northeast)](https://feeny.ai/job/senior-medical-science-liaison-northeast-summit-therapeutics-united-states-kz9wzmdv6wgq) — United States